Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Assets Average (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Assets Average for 4 consecutive years, with $264.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average fell 34.24% to $264.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $264.7 million, a 34.24% decrease, with the full-year FY2024 number at $357.0 million, down 15.74% from a year prior.
  • Assets Average was $264.7 million for Q3 2025 at Century Therapeutics, down from $300.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $541.4 million in Q2 2022 to a low of $264.7 million in Q3 2025.
  • A 4-year average of $404.8 million and a median of $392.5 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: decreased 1.18% in 2024, then plummeted 34.24% in 2025.
  • Century Therapeutics' Assets Average stood at $499.1 million in 2022, then fell by 24.05% to $379.1 million in 2023, then dropped by 2.16% to $370.9 million in 2024, then decreased by 28.64% to $264.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Assets Average are $264.7 million (Q3 2025), $300.2 million (Q2 2025), and $334.4 million (Q1 2025).